Testing nerandomilast for lung scarring from rheumatic disease
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests a new medicine called nerandomilast to see if it can help people with lung scarring caused by autoimmune rheumatic diseases like rheumatoid arthritis or scleroderma. The goal is to slow down lung damage and improve breathing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a rheumatic disease (like rheumatoid arthritis, scleroderma, or lupus-related conditions) that has caused scarring in your lungs.
- Your lung function has not improved significantly with current treatments in the past 15 months.
- Your lung capacity (FVC) is at least 45% of normal, and your lung’s ability to transfer oxygen (DLCO) is at least 25% of normal.
- You must be on a stable dose of your current medications (like immune-suppressing drugs or nintedanib) for several months before joining.
- You cannot have another lung condition like organizing pneumonia or a recent flare-up of your disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug called nerandomilast can slow down scarring in the lungs for people with certain types of fibrosing interstitial lung disease (a condition where lung tissue becomes thick and scarred). You may qualify if you have lung scarring that is getting worse and haven't tried this or similar drugs before.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
This trial tests if nerandomilast can help people with systemic sclerosis, a disease that can affect the skin and lungs. It may be an option for those with active disease and reduced lung function.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Hear when a new Interstitial Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.